Jade Biosciences (JBIO) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $7.12 to $7.58
• 50-Day Range: $6.76 to $11.14
• 52-Week Range: $6.57 to $105.00
• Volume: 77,779 shs
• Average Volume: 138,734 shs
• Market Capitalization: $6.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Jade Biosciences Stock Analysis - MarketRank™

Jade Biosciences scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Jade Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Jade Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Jade Biosciences is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jade Biosciences is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jade Biosciences has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for JBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jade Biosciences does not currently pay a dividend.

Dividend Growth

Jade Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for JBIO.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for JBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.90% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

JBIO Stock Analysis - Frequently Asked Questions

How have JBIO shares performed this year?

Jade Biosciences' stock was trading at $7.06 on January 1st, 2025. Since then, JBIO shares have increased by 6.1% and is now trading at $7.49.

Who are Jade Biosciences' major shareholders?

Jade Biosciences' top institutional investors include Geode Capital Management LLC (80.43%), Intech Investment Management LLC (2.73%), Deltec Asset Management LLC (1.88%) and Police & Firemen s Retirement System of New Jersey (0.85%).

How do I buy shares of Jade Biosciences?

Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JBIO
• CIK: 1798749
• Web: N/A
• Phone: (617) 443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jade Biosciences: $15.00
• High Price Target: $16.00
• Low Price Target: $14.00
• Potential Upside/Downside: +100.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($59.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.01%
• Return on Assets: -54.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 32.01
• Quick Ratio: 32.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $92.88 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 841,000
• Free Float: 632,000
• Market Cap: $6.30 million
• Optionable: N/A
• Beta: 1.03